There is some expectation that Eli Lilly's pipeline will break through, and analysts are particularly optimistic about diabetes and oncology treatments. Factors including these recent strong earnings, combined with a consensus Moderate Buy rating and a target price average of $1,002.22, constitute MarketBeat data.

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is in good financial shape but investors may be worried about its high valuation.